Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 3;14:970457. doi: 10.3389/fphar.2023.970457

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Arndt, Tunger, Wehner, Rothe, Kourtellari, Luttosch, Hannemann, Koristka, Loureiro, Feldmann, Tonn, Link, Kuhlmann, Wimberger, Bachmann and Schmitz.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of palbociclib and fulvestrant on bsAb-mediated tumor cell killing. T cells and (A,B) LNCaP-PSCA Luc+ or (C,D) PC3-PSCA/PSMA Luc+ cells were incubated with or without 30 nM of CD3-PSCA bsAb in the presence or absence of palbociclib and/or fulvestrant. After 8 h, tumor cell killing was calculated based on a luminescence-based killing assay. (A,C) Each diagram shows mean specific lysis ± SEM of triplicates for one T cell donor. (B,D) Graphs summarize relative tumor lysis ± SEM of three different T cell donors. Specific lysis in the presence of T cells and bsAb (“bsAb”) were equalized to 100%. (***p ≤ 0.001 compared to control sample “bsAb”; One-way ANOVA with posthoc Dunnett multiple comparison test).